Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y281
UPID:
COF2_HUMAN
Alternative names:
Cofilin, muscle isoform
Alternative UPACC:
Q9Y281; G3V5P4
Background:
Cofilin-2, also known as the muscle isoform of Cofilin, plays a pivotal role in muscle maintenance by controlling reversible actin polymerization and depolymerization in a pH-sensitive manner. It binds both G- and F-actin, facilitating the dynamic remodeling of the actin cytoskeleton, crucial for muscle fiber function and integrity.
Therapeutic significance:
Cofilin-2's involvement in Nemaline myopathy 7, a muscular disorder characterized by muscle weakness and abnormal muscle fibers, underscores its therapeutic potential. Understanding the role of Cofilin-2 could open doors to potential therapeutic strategies for treating muscle-related diseases.